Anthony DiPiazza

Anthony DiPiazza

Auto-generated profile, based on publicly available information

Anthony DiPiazza

Moderna Inc., Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2019 in Science
Verified
Journal Article
Closed access
MCMichelle C. Crank
Michelle C. Crank
TRTracy Ruckwardt
Tracy Ruckwardt
MCMan Chen
Man Chen
KMKaitlyn Morabito
Kaitlyn Morabito
EPEmily Phung
Emily Phung
AWAlicia Widge
Alicia Widge
Building a better RSV vaccine: Respiratory syncytial virus (RSV) causes severe respiratory disease, especially in infants and the elderly. However, attempts to produce effective human vaccines have largely been unsuccessful. Structure-based design has been used to generate an RSV fusion glycoprotein stabilized in its prefusion conformation (DS-Cav1). This immunogen is highly effective in mice and macaques. Crank et al. now report the results of a phase I vaccine clinical trial using the stabilized prefusion DS-Cav1 molecule. Four weeks after immunization, these vaccines elicited substantially more high-quality antibody titers than those typically generated using earlier RSV immunogens. The findings provide a proof of concept for how structural biology can contribute to precision vaccine design. Science , this issue p. 505

13 August 2021 in Science
Verified
Journal Article
Open access
PDF file
LWLingshu Wang
Lingshu Wang
TZTongqing Zhou
Tongqing Zhou
YZYi Zhang
Yi Zhang
EYEun Sung Yang
Eun Sung Yang
CSChaim A. Schramm
Chaim A. Schramm
JMJohn Misasi
John Misasi
Defenses against SARS-CoV-2 variants: Our key defense against the COVID-19 pandemic is neutralizing antibodies against the SARS-CoV-2 virus elicited by natural infection or vaccination. Recent emerging viral variants have raised concern because of their potential to escape antibody neutralization. Wang et al . identified four antibodies from early-outbreak convalescent donors that are potent against 23 variants, including variants of concern, and characterized their binding to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Yuan et al . examined the impact of emerging mutations in the receptor-binding domain of the spike protein on binding to the host receptor ACE2 and to a range of antibodies. These studies may be helpful for developing more broadly effective vaccines and therapeutic antibodies. —VV

1 January 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ADAnthony T. DiPiazza
Anthony T. DiPiazza
BGBarney S. Graham
Barney S. Graham
TRTracy Ruckwardt
Tracy Ruckwardt

26 June 2018 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
ASAndrea J Sant
Andrea J Sant
ADAnthony T. DiPiazza
Anthony T. DiPiazza
JNJennifer L. Nayak
Jennifer L. Nayak
ARAjitanuj Rattan
Ajitanuj Rattan
KRKatherine A. Richards
Katherine A. Richards

7 September 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ADAnthony DiPiazza
Anthony DiPiazza
ANAITOR NOGALES
AITOR NOGALES
NPNicholas Poulton
Nicholas Poulton
PWPatrick C. Wilson
Patrick C. Wilson
Luis Martinez-SobridoLuis Martinez-Sobrido
Luis Martinez-Sobrido
ASAndrea J Sant
Andrea J Sant
Although it is well established that Influenza A virus infection is initiated in the respiratory tract, the sequence of events and the cell types that become infected or access viral antigens remains incompletely understood. In this report, we used a novel Influenza A/California/04/09 (H1N1) reporter virus that stably expresses the Venus fluorescent protein to identify antigen-bearing cells over time in a mouse model of infection using flow cytometry. These studies revealed that many hematopoietic cells, including subsets of monocytes, macrophages, dendritic cells, neutrophils and eosinophils acquire influenza antigen in the lungs early post-infection. Surface staining of the viral HA revealed that most cell populations become infected, most prominently CD45negcells, alveolar macrophages and neutrophils. Finally, differences in infection status, cell lineage and MHC class II expression by antigen-bearing cells correlated with differences in their ability to re-stimulate influenza-specific CD4 T cellsex vivo. Collectively, these studies have revealed the cellular heterogeneity and complexity of antigen-bearing cells within the lung and their potential as targets of antigen recognition by CD4 T cells.

25 January 2016 in Frontiers in Immunology
Verified
Journal Article
Open access
ADAnthony DiPiazza
Anthony DiPiazza
KRKatherine A. Richards
Katherine A. Richards
ZKZackery A. G. Knowlden
Zackery A. G. Knowlden
JNJennifer L. Nayak
Jennifer L. Nayak
ASAndrea J Sant
Andrea J Sant
Recent events have made it clear that potentially pandemic strains of influenza regularly pose a threat to human populations. Therefore, it is essential that we develop better strategies to enhance vaccine design and evaluation, to predict those that will be poor responders to vaccination and to identify those that are at particular risk of disease-associated complications following infection. Simplified animal models have revealed the discrete functions that CD4 T cells play in the developing immune response and to influenza immunity. However, humans have a complex immunological history with influenza through periodic infection and vaccination with seasonal variants, leading to the establishment of heterogeneous memory populations of CD4 T cells that participate in subsequent responses. The continual evolution of the influenza-specific CD4 T cell repertoire involves both specificity and function and overlays other restrictions on CD4 T cell activity derived from viral antigen handling and MHC class II:peptide epitope display. Together, these complexities in the influenza-specific CD4 T cell repertoire constitute a formidable obstacle to predicting protective immune response to potentially pandemic strains of influenza and in devising optimal vaccine strategies to potentiate these responses. We suggest that more precise efforts to identify and enumerate both the positive and negative contributors within the CD4 T cell compartment will aid significantly in achievement of these goals.